←Back to Expert Scholars
Translational Medicine / 转化医学Pan RAS Inhibitors
Neal Rosen
MD, PhD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Member
110
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Neal Rosen has characterized MAPK pathway feedback that limits response to RAS and MEK inhibitors and informs pan RAS combination strategies. His work motivates combinations with SHP2 and vertical pathway inhibition. He is a leader in translational cancer pharmacology.
Share:
🧪Research Fields 研究领域
RAS
MAPK pathway
feedback signaling
SHP2
combination therapy
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Neal Rosen 的研究动态
Follow Neal Rosen's research updates
留下邮箱，当我们发布与 Neal Rosen（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment